Roche's Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early Alzheimer's disease, in yet another setback for an
The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.
A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen's Alzheimer's therapy Aduhelm being e
Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data drop for Alzheimer's therapy lecanemab – but a number of breakwaters could lie ahead.
